Overview

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Status:
Recruiting

Trial end date:
2024-08-19

Target enrollment:

Participant gender:

Summary

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Bevacizumab
Durvalumab